Manulife (Manufacturers Life Insurance)’s Apogee Therapeutics APGE Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.45M	Sell	33,559 -35,137	-51%	-$3.17M	﹤0.01%	1239
2026 Q1	$5.78M	Sell	68,696 -12,136	-15%	-$881K	0.01%	1093
2025 Q4	$6.12M	Buy	80,832 +17,607	+28%	+$1.11M	0.01%	1094
2025 Q3	$2.51M	Sell	63,225 -9,714	-13%	-$371K	﹤0.01%	1432
2025 Q2	$3.17M	Sell	72,939 -14,408	-16%	-$548K	﹤0.01%	1337
2025 Q1	$3.26M	Sell	87,347 -606	-0.7%	-$23.4K	﹤0.01%	1321
2024 Q4	$3.98M	Buy	87,953 +19,965	+29%	+$1.02M	﹤0.01%	1289
2024 Q3	$3.99M	Sell	67,988 -3,655	-5%	-$175K	﹤0.01%	1303
2024 Q2	$2.82M	Sell	71,643 -13,558	-16%	-$658K	﹤0.01%	1385
2024 Q1	$5.66M	Buy	85,201 +34,101	+67%	+$1.49M	0.01%	1137
2023 Q4	$1.43M	Buy	51,100 +1,745	+4%	+$35K	﹤0.01%	1629
2023 Q3	$1.05M	Buy	+49,355	New	+$1.09M	﹤0.01%	1705

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s APGE Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Apogee Therapeutics (APGE) stake by 51% in Q2 2026, selling an estimated $3.17M and leaving 33,559 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Manulife (Manufacturers Life Insurance) first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.12M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Manulife (Manufacturers Life Insurance) held 33,559 shares of Apogee Therapeutics worth $4.45M as of Q2 2026.
Manulife (Manufacturers Life Insurance) sold 35,137 Apogee Therapeutics shares in Q2 2026, an estimated $3.17M.
Apogee Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #1239 holding.
Manulife (Manufacturers Life Insurance) first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
Manulife (Manufacturers Life Insurance)'s Apogee Therapeutics position peaked at $6.12M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.